Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma

yf_tkr_BMY · 2026-08-19

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。